Details

Autor(en) / Beteiligte

• Lee, YongJu
• Ma, Hyo-Sun
• Callaway, Zak
• Kim, Chang-Keun

Titel

Montelukast treatment response according to eosinophil-derived neurotoxin level in children with allergic rhinitis

Ist Teil von

• The Journal of asthma, 2024-06, p.1-8

Ort / Verlag

England

Erscheinungsjahr

2024

Beschreibungen/Notizen

• Eosinophil-derived neurotoxin (EDN) is an important biomarker of eosinophilic inflammation. This study evaluated Montelukast treatment response according to EDN concentration in children with perennial allergic rhinitis (PAR). Fifty-two children with PAR were recruited and took a combination of Montelukast (5mg) and Levocetirizine (5mg) "Mont/Levo Group" or only Montelukast (5mg) "Mont Group" for 4 weeks. All caregivers were instructed to record rhinitis symptoms for 4 weeks. EDN was measured before and after treatment. Daytime nasal symptom scores (DNSS) significantly decreased in both the Mont/Levo (  = 0.0001; n = 20) and Mont Group (  < 0.0001; n = 20), but there were no significant differences between the two groups. EDN concentration also significantly decreased after treatment in both groups (  < 0.0001 and  < 0.001, respectively). For secondary analysis, children with a high initial EDN concentration (EDN ≥ 53 ng/mL) were placed in the "High EDN Group", while those with a lower initial EDN concentration (EDN < 53 ng/mL) were put in the "Low EDN Group". Both groups experienced significant reductions in DNSS after either treatment regimen (  < 0.0001 and  = 0.0027, respectively) but the High EDN Group had greater reductions. EDN concentrations in the High EDN Group decreased significantly from either treatment (  < 0.0001). We found that children with AR and a high serum EDN concentration may respond well to Montelukast treatment. A therapeutic strategy using EDN concentrations in patients with AR to evaluate therapeutic response may help improve quality of care.